Virus-like particle displaying SARS-CoV-2 receptor binding domain elicits neutralizing antibodies and is protective in a challenge model
J. L. McKechnie, B. Fiala, C. Wolf…·A. Feldhaus
This study develops a virus-like particle vaccine, IVX-411, that elicits neutralizing antibodies and provides protection against multiple SARS-CoV-2 variants in a challenge model.